Novartis India Limited Stock Price Today (NSE: NOVARTIND)
Fundamental Score
Novartis India Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Novartis India Limited share price today is ₹2428.20, up +11.06% on NSE/BSE as of 10 September 2026. Novartis India Limited (NOVARTIND) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.80K (Cr). The 52-week high for NOVARTIND share price is ₹2588.80 and the 52-week low is ₹950.00. At a P/E ratio of 40.76x, NOVARTIND is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 11.63% and a debt-to-equity ratio of 0.00.
Novartis India Limited Share Price Chart — NSE/BSE Historical Performance
Novartis India Limited share price chart: 13.35% return over the past month. 52-week high ₹2588.80, 52-week low ₹950.00.
Novartis India Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2260.00 | ₹2588.80 | ₹2232.10 | ₹2428.20 | 22.93L (Cr) | |
| ₹1873.70 | ₹2186.40 | ₹1851.00 | ₹2186.40 | 7.86L (Cr) | |
| ₹1659.00 | ₹1856.00 | ₹1640.10 | ₹1822.00 | 5.52L (Cr) | |
| ₹1661.20 | ₹1699.00 | ₹1602.50 | ₹1639.60 | 73.34K (Cr) | |
| ₹1614.90 | ₹1665.00 | ₹1614.90 | ₹1646.70 | 22.44K (Cr) | |
| ₹1610.00 | ₹1620.80 | ₹1585.60 | ₹1614.10 | 16.58K (Cr) | |
| ₹1585.00 | ₹1614.00 | ₹1560.20 | ₹1601.50 | 7.81K (Cr) | |
| ₹1546.60 | ₹1620.60 | ₹1541.60 | ₹1582.10 | 21.88K (Cr) | |
| ₹1487.00 | ₹1577.00 | ₹1480.00 | ₹1554.40 | 31.46K (Cr) | |
| ₹1488.50 | ₹1494.00 | ₹1471.20 | ₹1486.30 | 4.24K (Cr) |
Novartis India Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1546.60 | ₹2588.80 | ₹1541.60 | ₹2428.20 | +57.00% | |
| ₹1540.10 | ₹1681.60 | ₹1402.00 | ₹1554.40 | +0.93% | |
| ₹1430.00 | ₹1724.00 | ₹1430.00 | ₹1537.10 | +7.49% | |
| ₹1575.00 | ₹1589.20 | ₹1272.10 | ₹1434.40 | -8.93% | |
| ₹1030.00 | ₹1575.00 | ₹1013.00 | ₹1556.60 | +51.13% | |
| ₹991.00 | ₹1059.90 | ₹950.00 | ₹1030.50 | +3.99% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Novartis India Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Novartis India Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NOVARTIND across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Excellent ROCE Performance (16.25%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (18.81%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Excellent EPS Growth (34.88% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (34.88% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (103.90x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 5.25)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹317.74 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (70.68%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Premium Valuation Risk (P/E: 40.76x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (7.64x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Profit Decline Concern (-13.82%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (-1.46% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Limited Institutional Interest (FII+DII: 0.70%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Novartis India Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Novartis India Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Novartis India LimitedNovartis India ...Selected✓ NOVARTIND • 500672 | 53.2/100 | ₹2428.20₹2428 | ₹3797.75₹3797.75 | 40.76Average 40.8 Average | 11.63%Average 11.63% Average | 16.25%Good 16.25% Good | 0.00Excellent 0.0 Excellent | 34.88%Excellent 34.88% Excellent | -1.46%Poor -1.46% Poor | 1.62% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Novartis India Limited PE Ratio History
Historical price-to-earnings ratio for NOVARTIND — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2023 | ₹41.86 | ₹672.25 | 16.1x |
| FY 2021 | ₹8.46 | ₹776.20 | 91.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Novartis India Limited Dividend History
Annual cash dividends paid by NOVARTIND — dividend yield 1.62%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹61.73 Cr |
| FY 2024 | ₹117.28 Cr |
| FY 2023 | ₹24.69 Cr |
| FY 2022 | ₹24.69 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Novartis India Limited Quarterly Performance
Latest quarterly metrics for NOVARTIND — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
7.95%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-13.82%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-1.46%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
34.88%
Compounded annual net profit growth over 5 years
Novartis India Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for NOVARTIND — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Novartis India Limited Financial Statements
Annual income statement, balance sheet and cash flow for Novartis India Limited (NOVARTIND) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Novartis India Limited
About NOVARTIND (Novartis India Limited)
Novartis India Ltd is a prominent player in the Indian pharmaceutical landscape, dedicated to advancing healthcare solutions across a spectrum of therapeutic areas. With a strong c...ommitment to innovation and patient well-being, the company develops, manufactures, and markets a diverse portfolio of pharmaceutical products. These offerings address critical medical needs, contributing to improved health outcomes and enhanced quality of life for patients throughout India. Novartis India's unwavering focus on research and development ensures a continuous pipeline of innovative therapies, solidifying its position as a leader in the Indian pharmaceutical industry. The company's product range encompasses vital medications in diverse areas, most notably in bone and pain management with the well-established Voveran brand. Further extending its reach, Novartis India provides essential therapies in transplantation immunology, offering hope and improved outcomes for patients undergoing organ transplantation through brands like Simulect, Certican, Sandimmun, Neoral, and Myfortic. In the field of neuroscience, Novartis India contributes significantly by providing treatments for neurological disorders, with established brands such as Tegrital and Exelon, improving the lives of patients facing neurological challenges. Headquartered in the bustling city of Mumbai, India, Novartis India has a rich heritage dating back to its incorporation in 1947. As a subsidiary of the globally renowned Novartis AG, it leverages the parent company's extensive resources, cutting-edge research, and global network to deliver high-quality pharmaceutical products and services to the Indian market. Novartis India's presence is a testament to its enduring commitment to addressing the evolving healthcare needs of the nation, contributing to the overall health and well-being of the Indian population.
Company Details
Key Leadership
NOVARTIND Share Price: Frequently Asked Questions
What is the current share price of Novartis India Limited?
Novartis India Limited (NOVARTIND) trades at ₹2428.20 on NSE and BSE. Market cap ₹3.80K (Cr). Educational data only.
What is the P/E ratio of Novartis India Limited?
Novartis India Limited has a P/E of 40.76x vs industry average 34.89x.
What is the Bull Run score for Novartis India Limited?
Novartis India Limited has a Bull Run score of 53.2/100 based on 25+ financial parameters.
Does Novartis India Limited pay dividends?
Novartis India Limited has a dividend yield of 1.62%. Past dividends don't guarantee future payments.
What is the ROE of Novartis India Limited?
Novartis India Limited has ROE of 11.63%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Novartis India Limited?
Novartis India Limited has debt-to-equity of 0.00.
Is Novartis India Limited a good investment?
Bull Run gives Novartis India Limited a score of 53.2/100. This is not investment advice — consult a SEBI-registered advisor.